A large UK Biobank analysis reports that women who begin common hormone therapy in midlife, between about ages 46 and 56, have a lower risk of developing dementia, including Alzheimer’s disease. The reported association is roughly 23% lower risk compared with women who do not use the therapy.
The study’s results are based on observational data, meaning it can show a correlation rather than prove that hormone therapy prevents dementia. The sources agree that the findings concern hormone therapy as commonly prescribed and that timing of initiation in the 50s is a key factor in the reported risk difference. While the overall conclusion is similar across outlets, coverage emphasizes different aspects, such as the size of the risk reduction and whether the outcome is Alzheimer’s disease specifically or dementia more broadly.
Because observational studies can be influenced by differences in health status, healthcare access, and other factors between users and non-users, researchers typically call for additional research to clarify causality and identify which groups may benefit or face potential risks.
